Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Cubicin Rf Generic Name & Formulations
Legal Class
Rx
General Description
Daptomycin 500mg/vial; lyophilized pwd for IV inj after reconstitution (with sterile or bacteriostatic water for inj) or IV infusion after reconstitution and dilution; preservative-free; may be stored at room temperature.
Pharmacological Class
Cyclic lipopeptide.
See Also
How Supplied
Single-dose vial (10mL)—1
Manufacturer
Generic Availability
Cubicin vials (YES); Cubicin RF vials (NO)
Cubicin Rf Indications
Indications
Susceptible complicated skin and skin structure infections (cSSSI) in adults and pediatrics (1–17yrs). S. aureus bacteremia in adults (including MRSA and MSSA right-sided endocarditis) and in pediatrics (1–17yrs).
Limitations of Use
Not for treatment of pneumonia or left-sided endocarditis due to S. aureus. Not studied in prosthetic valve endocarditis. Not recommended in pediatrics (<1yr) due to risk of potential effects on muscular, neuromuscular, and/or nervous systems (peripheral and/or central).
Cubicin Rf Dosage and Administration
Adult
Give by IV inj over 2mins or IV infusion over 30mins. cSSSI: 4mg/kg once every 24hrs for 7–14 days. S. aureus bacteremia or endocarditis: 6mg/kg once every 24hrs for 2–6 weeks. Renal impairment (CrCl <30mL/min): decrease dosing interval to once every 48hrs; coincide dose for after dialysis.
Children
<1yr: not recommended. Give by IV infusion over 60mins (1–6yrs) or 30mins (7–17yrs). cSSSI (1–<2yrs): 10mg/kg once every 24hrs; (2–6yrs): 9mg/kg once every 24hrs; (7–11yrs): 7mg/kg once every 24hrs; (12–17yrs): 5mg/kg once every 24hrs. Treat up to 14 days. S. aureus bacteremia (1–6yrs): 12mg/kg once every 24hrs; (7–11yrs): 9mg/kg once every 24hrs; (12–17yrs): 7mg/kg once every 24hrs. Treat up to 42 days. Renal impairment (CrCl <30mL/min): not established.
Cubicin Rf Contraindications
Not Applicable
Cubicin Rf Boxed Warnings
Not Applicable
Cubicin Rf Warnings/Precautions
Warnings/Precautions
Monitor for development of muscle pain or weakness (esp. distal extremities). Monitor CPK weekly (more frequently in those with concomitant statin therapy or elevated CPK); discontinue if CPK (≥5×ULN) and myopathy occur, or if CPK (≥10×ULN) without myopathy occurs. Renal impairment: monitor renal function and CPK more frequently than once weekly. Discontinue immediately if eosinophilic pneumonia develops; treat with systemic steroids. Discontinue if tubulointerstitial nephritis or drug reaction with eosinophilia and systemic symptoms are suspected; treat appropriately. Monitor for neuropathy; consider discontinuation if occurs. Persisting or relapsing S. aureus bacteremia/endocarditis: repeat blood cultures and evaluate. Adults with moderate baseline renal impairment: decreased efficacy observed. Severe hepatic impairment. Pregnancy. Nursing mothers.
Cubicin Rf Pharmacokinetics
See Literature
Cubicin Rf Interactions
Interactions
Consider suspending agents associated with rhabdomyolysis (eg, statins). May cause false prolongation of PT or elevation of INR when certain recombinant thromboplastin reagents are utilized for the assay.
Cubicin Rf Adverse Reactions
Adverse Reactions
Diarrhea, headache, dizziness, rash, abnormal LFTs, elevated CPK, UTIs, hypotension, dyspnea, vomiting, abdominal pain, pruritus, pyrexia, sepsis, bacteremia, chest pain, edema, pharyngolarygeal pain, increased sweating, insomnia, hypertension; hypersensitivity reactions, myopathy, rhabdomyolysis, C. difficile-associated diarrhea.
Cubicin Rf Clinical Trials
See Literature
Cubicin Rf Note
Not Applicable
Cubicin Rf Patient Counseling
See Literature
